A review paper on Blue Light Cystoscopy (BLC™) with Hexvix®/Cysview® with focus on the use in the office setting with flexible cystoscopes was published on July 5, 2019, in the peer-reviewed European Medical Journal.
With emerging data confirming similar clinical benefits for flexible BLC in the surveillance of non-muscle invasive bladder cancer (NMIBC) to its current use in rigid cystoscopy, the authors state that there is a clear opportunity for flexible BLC to assert a central role in the treatment paradigm. In a clinical study, around 1 in 5 confirmed malignancies were detected only by flexible BLC (p<0.0001)1 and the introduction of flexible BLC for routine surveillance post-TURBT is supported by consensus among bladder cancer specialists2.
1 Daneshmand S et al. Efficacy and safety of blue light flexible cystoscopy with Hexaminolevulinate (HAL) in the surveillance of bladder cancer: A phase III, comparative, multi-center study. J Urol. 2018 Dec 2. pii: S0022-5347(17)78004-4. doi:10.1016/j.juro.2017.11.096.
2 Lotan Y, Bivalacqua TJ, Downs T, et al. Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA – Update 2018. Nat Rev Urol. 2019; pending. doi: 10.1038/s41585-019-0184-4. [Epub ahead of print].